243 related articles for article (PubMed ID: 20731355)
1. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
[TBL] [Abstract][Full Text] [Related]
2. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents.
Gurjar MK; Wakharkar RD; Singh AT; Jaggi M; Borate HB; Shinde PD; Verma R; Rajendran P; Dutt S; Singh G; Sanna VK; Singh MK; Srivastava SK; Mahajan VA; Jadhav VH; Dutta K; Krishnan K; Chaudhary A; Agarwal SK; Mukherjee R; Burman AC
J Med Chem; 2007 Apr; 50(8):1744-53. PubMed ID: 17373779
[TBL] [Abstract][Full Text] [Related]
4. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.
Hu Y; Lu X; Chen K; Yan R; Li QS; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(2):903-9. PubMed ID: 22192936
[TBL] [Abstract][Full Text] [Related]
6. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
Lee HY; Chang JY; Nien CY; Kuo CC; Shih KH; Wu CH; Chang CY; Lai WY; Liou JP
J Med Chem; 2011 Dec; 54(24):8517-25. PubMed ID: 22060033
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
Xue N; Yang X; Wu R; Chen J; He Q; Yang B; Lu X; Hu Y
Bioorg Med Chem; 2008 Mar; 16(5):2550-7. PubMed ID: 18226907
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.
Fürst R; Zupkó I; Berényi A; Ecker GF; Rinner U
Bioorg Med Chem Lett; 2009 Dec; 19(24):6948-51. PubMed ID: 19879758
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
11. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.
Mahal K; Biersack B; Caysa H; Schobert R; Mueller T
Invest New Drugs; 2015 Jun; 33(3):541-54. PubMed ID: 25678082
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
[TBL] [Abstract][Full Text] [Related]
14. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
Lee J; Kim SJ; Choi H; Kim YH; Lim IT; Yang HM; Lee CS; Kang HR; Ahn SK; Moon SK; Kim DH; Lee S; Choi NS; Lee KJ
J Med Chem; 2010 Sep; 53(17):6337-54. PubMed ID: 20690624
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
O'Boyle NM; Carr M; Greene LM; Bergin O; Nathwani SM; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
J Med Chem; 2010 Dec; 53(24):8569-84. PubMed ID: 21080725
[TBL] [Abstract][Full Text] [Related]
16. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
Arthuis M; Pontikis R; Chabot GG; Seguin J; Quentin L; Bourg S; Morin-Allory L; Florent JC
ChemMedChem; 2011 Sep; 6(9):1693-705. PubMed ID: 21732536
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
Simoni D; Romagnoli R; Baruchello R; Rondanin R; Grisolia G; Eleopra M; Rizzi M; Tolomeo M; Giannini G; Alloatti D; Castorina M; Marcellini M; Pisano C
J Med Chem; 2008 Oct; 51(19):6211-5. PubMed ID: 18783207
[TBL] [Abstract][Full Text] [Related]
20. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
Ohsumi K; Nakagawa R; Fukuda Y; Hatanaka T; Morinaga Y; Nihei Y; Ohishi K; Suga Y; Akiyama Y; Tsuji T
J Med Chem; 1998 Jul; 41(16):3022-32. PubMed ID: 9685242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
